Dr. Mims Discusses Momelotinib in Myelofibrosis

Alice S. Mims, MD
Published Online: Friday, Nov 10, 2017



Alice S. Mims, MD, assistant professor of medicine, The Ohio State University Comprehensive Cancer Center, discusses momelotinib in patients with myelofibrosis.

The SIMPLIFY-1 study investigated momelotinib to determine if it was non-inferior to ruxolitinib (Jakafi). It did show non-inferiority of splenic size for patients with myelofibrosis, states Mims.

The SIMPLIFY-2 attempted to determine if momelotinib was superior to ruxilitinib. It was not superior but there was improvement in anemia. There will be some role for momelotinib in the future for these patients, states Mims.
 


Alice S. Mims, MD, assistant professor of medicine, The Ohio State University Comprehensive Cancer Center, discusses momelotinib in patients with myelofibrosis.

The SIMPLIFY-1 study investigated momelotinib to determine if it was non-inferior to ruxolitinib (Jakafi). It did show non-inferiority of splenic size for patients with myelofibrosis, states Mims.

The SIMPLIFY-2 attempted to determine if momelotinib was superior to ruxilitinib. It was not superior but there was improvement in anemia. There will be some role for momelotinib in the future for these patients, states Mims.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Publication Bottom Border
Border Publication
x